Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

Leukemia

Volumn 12, Issue 2, 1998, Pages 144-149

  Todeschini, G ^a,b   Tecchio, C ^a   Meneghini, V ^a   Pizzolo, G ^a   Veneri, D ^a   Zanotti, R ^a   Ricetti, M M ^a   Solero, P ^a   Aprili, F ^a   Perona, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

Author keywords

Acute lymphoblastic leukemia; High dose daunorubicin

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ASPARAGINASE; BCR ABL PROTEIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; ITRACONAZOLE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BACTEREMIA; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG EMBOLISM; MALE; MYCOSIS; MYELITIS; ORAL DRUG ADMINISTRATION; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; T CELL LEUKEMIA;

EID: 0031951221     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400912     Document Type: Article

References (22)

1. Hoelzer D. Acute lymphoblastic leukemia. Progress in children, less in adults. New Engl J Med 1993; 329: 1343-1344.
2. Rohatiner AZS, Lister TA. The challenge of acute lymphoblastic leukaemia in adults. Br J Haematol 1993; 85: 641-645.
3. Radford JE Jr, Burns PC, Jones MP, Gingrich RD, Kemp JD, Edwards RW, McFadden DB, Dick FR, B-Chen Wen. Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol. J Clin Oncol 1989; 7: 58-66.
4. Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, Arlin Z, Berman E, Kempin S, Gee T, Clarkson B, A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1960; 6: 1014-1030.
5. Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rulh H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, Gereche D, Pralle H, Muller U, Lunschken Ch, Fulle H, Ho AD, Kuchler R, Busch FW, Schneider W, Gorg Ch, Emmerich B, Braumann D, Vaupel HA, Von Paleske A, Bartels H, Neiss A, Messerer D. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
6. Bassan R, Battista R, D'Emilio A, Viero P, Dragone P, Dini E, Barbui T. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukemia. Eur J Cancer 1991; 27: 441-447.
7. Hussein KK, Dahlberg S, Head D, Waddel CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Riukin SE, Grever MR, Boldt D and the Southwest Oncology Group. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. Blood 1909; 73: 57-63.
8. Omura GA, Moffitt S, Vogler WR, Salter MM, (Writing Committee for the Southeastern Cancer Study Group). Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980; 55: 199-204.
9. Larson RA, Dodge RK, Burns PC, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Hartur DC, George SL, Bloomfield CD, Schiffer CA. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 0811. Blood 1995; 85: 2025-2037.
10. Todeschini G, Meneghini V, Pizzolo G, Cassibba V, Ambrosetti A, Veneri D, Nadali G, Zanotti R, Tecchio C, Perona G, Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994; 8: 376-381.
11. Todeschini G, Tecchio C, Depani D, Meneghini V, Marradi P, Balter R, Zanotti R, Ricetti M, Franchini M, Perona G. 81% EFS in advanced Burkitt lymphoma: no difference in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997; 8 (Suppl. 1): S77-S81.
12. Rivera GK, Buchanan G, Boyett JM, Comitta B, Ochs J, Kalwinsky D, Amylon M, Vietti TJ, Crist WM. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. New Engl J Med 1986; 315: 273-281.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
14. Todeschini C, Scognamiglio F, Sheiban I, Tonni S, Pizzolo G, Tecchio C, Meneghini V, Perona G. Lack of cardiac side-effects following high-dose treatment of daunomycin in adult acute lymphoblastic leukemia. Blood 1996; 80 (Suppl. 1): Abstr. 3408.
15. Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol 1994; 12: 1312-1322.
16. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984; 64: 267-274.
17. Cassileth PA, Andersen JW, Bennett JM, Hoagland HC, Mazza JJ, O'Connell MC, Paietta E, Wiernik P for the Eastern Cooperative Oncology Group. Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group Experience. Leukemia 1992; 6(Suppl. 2): 178-181.
18. Rivera GK, Crist WM. Acute lymphoblastic leukemia. In: Handin RI, Stosel TP, Lux SE (eds). Blood: Principles and Practice of Hematology. JB Lippincott: Philadelphia, 1995, pp 743-782.
19. Dekker AW, van't Veer MB, Haak HL, van der Lelie J, Ossenkoppele G, Schouten HC, Sonneveld P, van Putten WLJ, Willemze R, Lowenberg B. Conventional remission induction followed by intensive consolidation without maintenance therapy in adult acute lymphoblastic leukemia. Results from a phase II clinical trial in 130 patients. Blood 1994; 84: 144a (Abstr.).
20. Linker CA, Ries CA, Damon LE, Rugo HS. Pilot study of intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. Blood 1994; 84: 143a (Abstr.).
21. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80: 280-291.
22. Evensen SA, Brinch L, Tjonnfjord G, Stavem P, Wisloff FF. Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia. Br J Haematol 1994; 88: 88-93.